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ABSTRACT
Purpose: To investigate dynamic contrast enhanced-MRI (DCE-MRI) in the 
preoperative chemo-radiotherapy (CRT) assessment for locally advanced rectal cancer 
(LARC) compared to18F-fluorodeoxyglucose positron emission tomography/computed 
tomography (18F-FDG PET/CT).
Methods: 75 consecutive patients with LARC were enrolled in a prospective study. 
DCE-MRI analysis was performed measuring SIS: linear combination of percentage 
change (Δ) of maximum signal difference (MSD) and wash-out slope (WOS). 18F-FDG 
PET/CT analysis was performed using SUV maximum (SUVmax). Tumor regression 
grade (TRG) were estimated after surgery. Non-parametric tests, receiver operating 
characteristic were evaluated.
Results: 55 patients (TRG1-2) were classified as responders while 20 subjects 
as non responders. ΔSIS reached sensitivity of 93%, specificity of 80% and accuracy 
of 89% (cut-off 6%) to differentiate responders by non responders, sensitivity of 
93%, specificity of 69% and accuracy of 79% (cut-off 30%) to identify pathological 
complete response (pCR). Therapy assessment via ΔSUVmax reached sensitivity of 67%, 
specificity of 75% and accuracy of 70% (cut-off 60%) to differentiate responders 
by non responders and sensitivity of 80%, specificity of 31% and accuracy of 51% 
(cut-off 44%) to identify pCR.
Conclusions: CRT response assessment by DCE-MRI analysis shows a higher 
predictive ability than 18F-FDG PET/CT in LARC patients allowing to better discriminate 
significant and pCR.
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INTRODUCTION
Approximately forty thousand new cases of rectal 
cancer are accounting in the USA in 2015 [1]. Despite the 
introduction of the screening programs, several patients are 
diagnosed in a locally advanced stage. Preoperative radio-
chemotherapy (pCRT) associated with total mesorectal 
excision (TME) is the standard care procedure for locally 
advanced rectal cancer (LARC) [2, 3]. TME is linked to 
morbidity and complications, therefore in clinical practise 
there is an increase of conservative treatment strategies 
application for patients with substantial tumor regression 
after pCRT and “wait and see” policy for patients with 
complete pathological regression. The advantage of this 
strategy is the reduction of morbidity and the possibility to 
provide a “true” organ-sparing approach. In this scenario 
is necessary to individuate the selection criteria for these 
strategies that accurately can assess neoadjuvant treatment 
response. Morphological MRI (mMRI) is the best tool for 
local LARC staging, permitting a correct assessment of 
the disease extent, of the mesorectal fascia and lymph 
node involvement [4, 5]. On the other hand, there are some 
limits to detect changes after pCRT by means of mMRI 
[4]. A positive tumor response may not correspond to a 
significant tumor size reduction. Moreover, it is difficult to 
discriminate between post treatment fibrosis and residual 
viable tumor using morphological approach. To overcome 
this limitation, functional approaches that aim to assess 
tissue “viability” through different imaging modalities 
such as Position Emission Tomography, Dynamic Contrast 
Enhanced-Magnetic Resonance Imaging (DCE-MRI), 
Diffusion Weighted Magnetic Resonance Imaging (DWI) 
are being actively investigated. One widely used approach 
is Positron Emission Tomography coupled with Computed 
Tomography (PET/CT) that in rectal cancer management 
is capable to early predict treatment response [6–10]. 
However, among data reported in literature [7–8, 10], 
late PET scans, performed before surgery, showed lower 
accuracy in pathologic response assessment.
Some authors described the value of mMRI and 
additional 18F-fluorodeoxyglucose positron emission 
tomography/computed tomography (18F-FDG PET/CT) 
for pCRT tumor response evaluation in patients with 
LARC [7, 8]. In Huh et al. [7] sensitivity, specificity 
and diagnostic accuracy of mMRI to predict pathologic 
complete response were 38.5%, 58.1% and 55.2%, 
respectively. Using a response index (percentage change 
of Standardized Uptake Value maximum, ΔSUVmax) of 
63.6%, it was possible to detect the complete response 
response with a sensitivity of 73.1%, a specificity of 
64.5% and an accuracy of 65.7%. Aiba et al. [8] have 
shown no benefit adding 18F-FDG PET/CT to mMRI in 
assessment of pCRT responders based on changes in area 
under receiver operating characteristic curve. To the best 
of our knowledge, there are no available studies in the 
literature on an enough number of patients that directly 
compare functional parameters obtained by18F-FDG PET 
and DCE-MRI in the pre-surgical evaluation of CRT 
in LARC. Using these imaging methods with the same 
timing allows exploring potential existing relationships 
between two different functional tissue proprieties: tumor 
vascularity investigated by tissue perfusion and tissue 
glucose metabolism [11–25].
In a previous study, we investigated a semi-
quantitative analysis with DCE-MRI [14–20], finding 
the best combination, denominated Standardized Index 
of Shape (SIS), that identifies the linear classifier 
of the percentage differences Δ of Maximum Signal 
Difference (MSD) and of Wash-Out Slope (WOS) [7], 
with a sensitivity and specificity of 93.5% and 82.1% in 
discrimination of responder by non responder patients 
after pCRT [13].
The objective of this study was to validate the 
potential of SIS analysis in LARC to identify significant 
and pathological complete response after neoadjuvant 
preoperative CRT, in comparison with 18F-FDG PET.
RESULTS
For both examinations, PET/CT and DCE-MRI, the 
temporal range between baseline and preoperative scan 
were 90 days (± 15). The median interval between the end 
of CRT and TME was 9 weeks for both regimen (range, 
7–14). All patients in our series had a radical resection 
with an undamaged and complete mesorectum. Patient 
characteristics and clinical staging including Gunderson 
Risk [25], distance by anal verge, circumferential 
resection margin were reported in Table 1. 27 patients 
were classified as pT0 (pathological T), 7 as pT1, 31 as 
pT2, 9 as pT3, and 1 as pT4. There were 30 patients with 
a tumour regression grade (TRG) equal to 1, 25 with a 
TRG = 2, 10 with a TRG = 3, 10 with a TRG = 4, and 
none with a TRG = 5. Then, based on TRC classification 
55 (73.3%) patients were classified as responders (TRG = 
1-2) and 20 (26.7%) as non-responders (TRG = 3-4). No 
significant differences between pathological responders 
and non-responders could be found regarding patients 
characteristics (Table 1).
Median values for ΔSIS and ΔSUVmax for responder 
and non-responder patients according to TRG (TRG 
1-2 vs TRG 3-4) and pathological T (pT 0-2 vs pT3-4) 
are reported in Table 2. Mann-Whitney test showed 
statistically significant differences for ΔSIS and ΔSUVmax 
median values between responders and non-responders 
patient based on TRG. Statistically significant differences 
based on pT were only found for ΔSIS values (Table 2).
Figure 1a shows ROC analysis for ΔSIS and 
ΔSUVmax in discriminating responders from non 
responders. The optimal cut-off for ΔSIS was a reduction 
of 6.0% yielding 92.7% of sensitivity and 80.0% of 
specificity to identify responder patients. Instead, the 
optimal cut-off of 59.7% for ΔSUVmax showed lower 
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accuracy in identifying responder patients than ΔSIS, 
with a sensitivity of 67.3% and a specificity of 75.0%. 55 
patients were classified as responders by ΔSIS, including 
51 true positives, while 41 patients were classified as 
responders by ΔSUVmax, including 37 true positives. 
The combination of ΔSIS and ΔSUVmax did not increase 
predictive ability, classifying 43 patients as responders, 
of whom only 36 were true pathological responders. 
Figure 1b shows ROC analysis for ΔSIS and ΔSUVmax in 
discrimination pathological complete response (TRG1) 
by incomplete response (TRG 2-4). The optimal cut-off 
for ΔSIS was a reduction of 30.3% (93.3% of sensitivity 
and 68.9% of specificity) while the optimal cut-off of 
43.9% for ΔSUVmax showed lower accuracy (sensitivity of 
80.0% and specificity of 31.1%). Statistically significant 
differences between ΔSIS and ΔSUVmax, in terms of 
both sensitivity and specificity, were assessed using the 
McNemar test (p value <0.05), for both analysis. The 
presurgical PET/CT analysis demonstrated a low level of 
correlation between median ΔSUVmax value with pT and 
TRG findings (Spearman's rank correlation coefficient 
= -0.2 and -0.3, respectively), while a good level of 
correlation was observed between median ΔSIS value and 
pT and between median ΔSIS value and TRG (Spearman's 
rank correlation coefficient = -0.6 and -0.7, respectively). 
Table 3 shows the performance of ΔSIS and ΔSUV 
analysis to identify responder from non-responder patients 
and complete by incomplete pathological response. 
Figures 2 and 3 show DCE-MRI and 18F-FDG PET/CT 
images respectively, for a responder patient (TRG = 1). 
Figures 4 and 5 respectively show DCE-MRI and 18F-FDG 
PET/CT images, for another responder patient (TRG = 2)
recognized only to ΔSIS analysis.
Table 1: Patient Characteristics and Clinical Staging
Characteristics All patients n=75 (%) TRG 1–2 n= 55 TRG 3–4 n=20 p*
Gender >0.05
 Male/Female 50(67)/25(33) 37/18 13/7
 Median age (range) 62(44-77) 62(44-77) 63(44-76)
Gunderson Risk (25) >0.05
 Intermediate: T3N0 4(5.3) 3 1
 Moderately high: T3N1, T4N0 26 (34.7) 17 9
 High: T3N2, T4N1-2 45 (60.0) 33 12
Distance from the anal verge >0.05
 ≤ 5 cm 37(49) 28 9
 > 5 cm 38(51) 27 11
Circumferential resection margin >0.05
 > 2 mm 32(43) 26 2
 >1 and ≤ 2 mm 9(12) 7 2
 ≤ 1 mm 30(40) 20 10
 Not mesurable 4(5) 2 2
*Chi-square test or Mann- Whitney U Test
Table 2: ΔSIS and ΔSUVmax median values for patients subgroups depending on TRG and pT score
All patients n=75 TRG 1–2 n= 55 TRG 3–4 n=20 p*
ΔSUVmax median (standard deviation) 62%(36) 73%(37) 48%(30) < 0.001
ΔSIS median (standard deviation) 36%(65) 57%(49) -18%(73) < 0.001
pT 0–2 n= 65 pT 3–4 n=10 p*
ΔSUVmax median (standard deviation) 66 (36) 58 (34) >0.05
ΔSIS median (standard deviation) 42 (59) -20 (80) < 0.001
* Mann- Whitney U Test
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DISCUSSION
The aim of the study was validate the potential of 
DCE-MRI (by means of ΔSIS value) in comparison to 
PET/CT (by means of ΔSUVmax) to evaluate preoperative 
neoadjuvant CRT response in LARC patients. There 
is a growing need to optimize the multidisciplinary 
management of patients with LARC, considering on 
the one hand that tumour response and patient benefit 
from CRT may considerably vary and on the other that 
preoperative treatment and TME are not completely free 
from serious early and late morbidity. In this scenario, the 
identification of patients with TRG 1–2, usually associated 
with a low prevalence of nodal involvement and a better 
outcome [26], would allow candidates to be selected for 
conservative mini-invasive strategies or for a “wait-and-
see” policy [27–29].
Some authors reported the value of DCE-MRI based 
on semi-quantitative parameters such as initial slope, 
initial peak, late slope, and area under time intensity 
curve [30] or kinetic features (Ktrans, kep, ve) [31] in 
the evaluation of pathological complete response to 
pCRT in LARC. Martens et al. [30] concluded that “late 
slope” derived from DCE-MRI analysis using a semi-
quantitative approach could predict before the beginning 
of pCRT which tumors are likely going to respond. Tong 
et al. [31] concluded that DCE-MRI could differentiate 
between pathological complete and incomplete pCRT 
response using a Ktrans threshold value of 0.66 reaching 
the 100% of sensitivity. Furthermore, some studies 
have shown how PET evaluation can predict pathologic 
tumor response and outcome after preoperative CRT in 
LARC patients, suggesting its great potential in assisting 
physicians on individualized management decisions in this 
disease [7–8, 10]. Several authors studied the benefit of 
apparent diffusion coefficient (ADC) of DWI and SUV 
of PET/CT in the assessment of pCRT response in LARC 
[32–34] showing that their combination allows to increase 
the sensitivity of the correct detection of response than 
either approach alone. However, a systematic review 
[34] reported a low positive predictive value (PPV) to 
predict pathological complete response (PPV of 54% and 
39% for DWI and PET/CT, respectively). Baseline CRT 
imaging is not capable to forecast pathological complete 
response with overall accuracies of 68-72% for DWI 
and 44% for PET/CT. Qualitative DWI evaluation after 
CRT (5-10 weeks after the end) may outperform apparent 
diffusion coefficient reaching an overall accuracy of 87% 
versus 74-78%. The major strength of DWI and PET/CT 
is the capability to identify the non-responder patients 
who are not candidates for organ preservation. However, 
both DWI and PET/CT are not accurate enough to safely 
identify patients candidates for conservative mini-invasive 
treatments of for “wait and watch” policy allowing organ-
sparing.
Our results show that ΔSUVmax, between basal 
and pre-surgery SUV values, showed a significant 
correlation to TRG (AUC 0.71) with a sensitivity of 
67.3%, a specificity of 75.0% and an accuracy of 69.7%, 
considering the optimal cut-off value of 59.7% provided by 
ROC analysis while a lower accuracy is shown to identify 
pathological complete response (sensitivity of 80.0% and 
specificity of 31.1%). Moreover, our results showed that 
ΔSUVmax median values were statistically different at 
Figure 1: A. ROC analysis for ΔSIS and ΔSUVmax in discriminating responders from non responders. Cut-off value in ΔSIS (black line, 
AUC = 0.86) changed of 6.0% yields 92.7% of sensitivity and 80.0% of specificity. Cut-off value in ΔSUVmax (blue line, AUC = 0.71) of 
59.7% gave a sensitivity of 67.3% and a specificity of 75.0%. B. ROC analysis for ΔSIS and ΔSUVmax to identify pathological complete 
response. Cut-off value in ΔSIS (black line, AUC = 0.82) changed of 30.3% yields 93.3% of sensitivity and 68.9% of specificity. Cut-off 
value in ΔSUVmax (blue line, AUC = 0.57) of 43.9% gave a sensitivity of 80.0% and a specificity of 31.1%. The two red rectangles highlight 
the sensitivities and specificities corresponding to the optimal thresholds.
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Figure 2: Patient n. 64: T2-weighted images in axial A and sagittal C plane before B and after treatment D The morphologic images (A 
and C) before CRT, showed heterogeneous irregular thickening along the rectal wall spreading into the perirectal fat (A, arrowheads). After 
CRT, a hypointense area relating to rectal wall thickening is still visible (B and D, arrowheads). Median Time intensity curve of volume of 
interest (E and G), segmented by expert radiologist, before treatment is shown in F and after treatment in H These curves showed different 
contrast enhancement, with a ΔSIS of 31.93% classifying the patient as responder.
Table 3: Diagnostic Performance of ΔSIS and ΔSUVmax
Cut-off % Sensitivity % Specificity % PPV % NPV % ACC % AUC
To differentiate responders (TRG1-2) by non responders (TRG 3-5)
ΔSUVmax 59.7 67.3 75.0 88.1 45.5 69.7 0.71
ΔSIS 6.0 92.7 80.0 92.7 80.0 89.3 0.86
To differentiate complete pathological response (TRG) by incomplete response (TRG 2-5)
ΔSUVmax 43.9 80.0 31.1 43.6 70.0 50.7 0.57
ΔSIS 30.3 93.3 68.9 66.7 93.9 78.7 0.82
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Figure 4: Patient n. 68: T2-weighted images in axial A and sagittal C plan B before the treatment and after treatment D The morphologic 
images (A and C) before CRT, showed heterogeneous irregular thickening along the rectal wall spreading into the perirectal fat (A, and 
C arrowheads). After CRT, a hypointense area with thickening of the rectal wall and straining into perirectal fat (B and D, arrowheads) is 
observed. Median Time intensity curve of the volume of interest E and G, before F and after treatment H are shown. These curves showed 
different contrast enhancement, with a ΔSIS value of 39.54% classifying the patient as responder.
Figure 3: 18F-FDG PET/CT images before A and after B treatment showed a reduction of FDG uptake with a ΔSUVmax of 96.67% 
classifying the patient as responder.
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Mann-Whitney U test for responder and not responder 
patients based on TRG. These findings with 18F-FDG PET/
CT, using Standardized Uptake Value, are in agreement 
with previous results [10, 35–38]. Avallone et al. [10] 
reported that early changes of SUVmax were predictive 
of pathological response with an optimal threshold value 
of -42.0% and an accuracy of 93.0%. In this study, the 
authors also observed that the findings obtained from 
late PET scans, performed before surgery, showed lower 
accuracy in predicting pathologic response. Leccisotti et 
al. [35] evaluated metabolic modifications in the tumour 
during and after pCRT in 124 patients affected by LARC. 
A reduction of 61.2% of SUV was the best threshold 
to depict complete pathological response obtaining a 
85.4% of sensitivity and a 65.2% of specificity while 
they [35] did not identify the optimal cut-off for the late 
response after PCRT. Leccisotti et al. [35] concluded that 
the PET/CT can predict early pCRT response depicting 
non-complete responders and allowing modification of 
treatment; contrariwise, late response before surgery is 
not sufficiently accurate for guiding the surgical decision 
versus TME, conservative strategies or observation over 
time. Niccoli-Asabella et al. [36] reported similar findings. 
Kim et al. [37] demonstrated that post-CRT SUVmax had 
a sensitivity of 60.4%, a specificity of 65.0%, and an 
accuracy of 55.9 %. Palma et al. [38] reported that post-
CRT SUVmax had a sensitivity of 45.0%, a specificity of 
70.0%, and an accuracy of 60.0%. Similar results were 
observed on advanced esophageal cancer [39]. Overall 
these data show the poor accuracy of late metabolic 
response to predict pathological responses, while they 
support the usefulness of performing PET/CT early during 
preoperative CRT in LARC.
Using ΔSIS analysis, we obtained better results 
than ΔSUVmax, both in terms of sensitivity (92.7%), 
negative predictive value (92,7%) and accuracy (89.3%), 
considering the optimal threshold of 6.0%. These results 
are comparable with the findings reported in our previous 
paper [13] where ΔSIS percentage variation obtained 
a sensitivity of 93.5% and a specificity of 82.1%. ΔSIS 
showed a statistically significant difference in median 
values for responder and non-responder patients based on 
TRG and pathological T stage. In addition, a good linear 
correlation between ΔSIS median values and TRG score 
(Spearman's rank correlation coefficient = -0.7), was also 
observed.
Diagnostic performance of ΔSIS to assess 
preoperative CRT response was statistically significant 
in comparison of ΔSUVmax performance resulting an 
increase of sensitivity of 25.4% and an increase of 
negative predictive value of 34.5% (McNemar test p 
value <0.05). Moreover, an increase of ΔSIS diagnostic 
performance respect to ΔSUVmax was also observed in 
the differentiation of pathological complete response by 
incomplete response (ΔSIS cut-off of 30%): 13.3% of 
sensitivity increase, 37.8% of specificity increase, 23.1% 
of PPV increase and 23.9% of NPV increase. However, 
18F-FDG PET/CT evaluation remains a more widely 
applicable approach to predict neo-adjuvant therapy 
response in LARC, whereas SIS is for the time being a 
promising DCE-MRI angiogenic biomarker with great 
potential for assessing preoperative treatment response and 
directing surgery for more or less conservative treatment.
The heterogeneity in the neoadjuvant treatment 
scheme with the majority of study population receiving 
an experimental schedule of “antiangiogenic” agent 
plus oxaliplatin in comparison of standard CRT scheme 
was previously investigated in the our study [13]. The 
analysis in [13] showed that the treatment schedule did not 
influence the proportions in responder and non-responder 
patients.
Some potential limitations deserve a special 
consideration: two radiologists assessed the MR images 
in agreement and in a single session per patient so that 
Figure 5: 18F-FDG PET/CT images before A and after B treatment demonstrating a minimal reduction of glucose metabolism with 
ΔSUVmax of 6.07% classifying the patient as non responder.
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the intra-observer variability analysis was not performed. 
Butylscopolamine, dicyclomine, glucagon or similar 
drugs were not administered; however we performed 
volumetric analysis that minimize errors due to caused 
voxel misalignments.
Future improvement of this application could be 
the 1) development of an easy to use and user friendly 
SIS evaluation software, 2) comparison of SIS analysis 
with diffusion and perfusion coefficients obtained by 
Diffusion Weighted Imaging data analysis, 3) combination 
of multiple functional biomarkers (SIS, SUV, Diffusion 
Coefficients) to early predict neoadjuvant therapy response 
in LARC.
In conclusion, our study proposes an imaging 
angiogenetic biomarker, the Standardized Index of Shape, 
as an objective measurable index, easily transferable 
to clinical routine through a user-friendly software 
application, able to assess pCRT tumor response with a 
reproducible semi-quantitative measure of tumor blood 
perfusion. SIS percentage change could play an important 
role in LARC management helping to identify significant 
pathological response in order to adopt conservative 
strategies and to detect complete pathological response in 
order to guide versus a “wait and see” policy, reducing 




75 consecutive patients - with a median age of 
62 years (range 44-77 years) were enrolled in this 
prospective study, from March 2007 to June 2014. All 
patients had a biopsy-proven rectal adenocarcinoma. 
Endorectal ultrasonography, pelvis MRI and whole 
body contrast enhanced CT scans were used for staging. 
Inclusion criteria were: patients with clinical T3-4 or with 
nodal involvement. Exclusion criteria were: inability 
to give informed consent, previous rectal surgery and 
contraindications for undergoing MRI or administering 
MR contrast media. Fifty-four (72%) patients had been 
enrolled in a phase II prospective trial previously described 
[9]. The study was approved by the Independent Ethical 
Committee of our institution. All patients gave written 
informed consent to participate to the study.
Neoadjuvant therapy and surgical approach
External radiation therapy was performed using a 
3-field technique (one posterior-anterior and two lateral 
fields). Standard fractions of 1.8 Gy/day to the reference 
point were given, 5 times a week up to a total dose of 45 
Gy. Details of treatment planning have been previously 
reported [9]. Fifty-four patients received an experimental 
treatment with biweekly bevacizumab at 5 mg/kg plus 
three biweekly cycles of oxaliplatin at 100 mg/m2 and 
raltitrexed at 2.5 mg/m2 on day 1, and levo-folinic acid at 
250 mg/m2, and 5-Fluorouracil at 800 mg/m2 on day 2 [8]. 
21 remaining subjects received standard treatment with 
capecitabine at a dose of 825 mg/m2 twice daily, 5 days a 
week, for 5 weeks.
Patients underwent TME 8 (±1) weeks after 
completing CRT. An anterior or abdominoperineal 
resection was performed on the basis of the results of 
restaging.
FDG-PET data acquisition and analysis
PET studies were acquired 60 min after the 
administration of 300–385 MBq of FDG either with a 
General Electric Discovery DST 600 PET/CT scanner 
Table 4: Pulse Sequence Parameters on MR studies





T1w 2D TSE Coronal 499/13/150 2.36 450x450 256x230 3 / 0 3
T2w 2D TSE Sagittal 4820/98/150 4.17 260x236 256x139 3 / 0 13
T2w 2D TSE Coronal 4820/98/150 4.17 260x236 256x139 3 / 0 13
T2w 2D TSE Axial 3970/98/150 3.48 270x236 256x157 3 / 0 13
T1w FLASH 3D Axial 9.8/4.76/25 0.58 330x247 256x192 3 / 0 /
T1w FLASH 3D Axial 9.8/4.76/25 0.58x10 330x247 256x192 3 / 0 /
T1w 2D TSE Sagittal 538/13/150 2.35 250x250 256x230 3 / 0 5
T1w 2D TSE Coronal 538/13/150 2.52 250x250 256x230 3 / 0 5
T1w 2D TSE Axial 450/12/150 2.31 270x236 256x202 3 / 0 5
Abbreviations: TR = Repetition Time, TE = Echo Time, FOV = Field of View, FA = Flip Angle, ST = Slice Thickness, 
TF = Turbo Factor, AT = Acquisition Time
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[10]. All calibrations on the scanners to obtain accurate 
SUV readings were regularly performed. Patients fasted 
for at least 6 h, and blood glucose level was <150 mg/dl. 
Each patient underwent the baseline and the pre-operative 
study on the same scanner.
18F-FDG PET/CT image assessment was performed 
in a single reading session for each patient by consensus of 
two expert investigator with at least 15 years of experience. 
The readers were blinded to the clinicopathologic outcome 
and MRI findings. Irregular volumes of interest (VOIs) 
were semi-automatically drawn on orthogonal planes 
using a dedicated workstation and software using an 
arbitrary threshold, as reported previously [10]. For each 
patient both studies were analyzed at the same time in 
order to minimize discrepancies in VOI positioning. 
For each study maximum SUV (SUVmax) values of the 
rectal lesion were recorded. FDG PET analysis results 
was performed by comparing measurements obtained in 
the rectal lesion at baseline (SUV1) and after treatment 
(SUV2). This change (known also as response index) was 
expressed as the percentage of SUV reduction (ΔSUV = 
(SUV1−SUV2)/SUV1×100) [9].
MRI data acquisitions
All patients underwent DCE-MRI before and 
after CRT. Imaging was performed with a 1.5T scanner 
(Magnetom Symphony, Siemens Medical System, 
Erlangen, Germany) equipped with a phased-array body 
coil. Patients were placed in a supine, head-first position. 
Mild rectal lumen distension was achieved with 60-90 mL 
of undiluted ferumoxil (Lumirem, Guerbet, Roissy CdG 
Cedex, France) suspension introduced per rectum in order 
to obtain mild distension of rectal lumen [21] and improve 
the evaluation of rectal wall involvement, particularly in 
the post contrast MR scan. Pre-contrast coronal T1w 2D 
turbo spin-echo images and sagittal, coronal and axial T2w 
2D turbo spin-echo images of the pelvis were obtained. 
Subsequently, axial, dynamic, contrast-enhanced T1w, 
FLASH 3D gradient-echo images were acquired for semi-
quantitative MRI analysis. We obtained one sequence 
before and ten sequences, without any delay, after the IV 
injection of 0.2 mL/kg of a positive, gadolinium-based 
paramagnetic contrast medium (Gd-DOTA, Dotarem, 
Guerbet, Roissy CdG Cedex, France). The contrast 
medium was administered using a Spectris Solaris® 
EP MR (MEDRAD Inc., Indianola, PA) injector, with a 
flow rate of 2 mL/s, followed by a 10-mL saline flush at 
the same rate. Sagittal, axial and coronal post-contrast 
T1w 2D turbo spin-echo images, with and without fat 
saturation were obtained. The axial images were acquired 
without any angulation. Axial T1-w pre- and post-contrast 
sequences were acquired at the same position as the T2-w 
sequence. MRI total acquisition time was around 30 
minutes. Sequence parameters details were reported in 
Table 4.
Spin-echo diffusion-weighted echo-planar imaging 
at different b values was performed for a limited subgroups 
of patients for this reason is not effected its analysis in this 
manuscript but could be object of a future study.
MRI image data analysis
Image assessment was performed in a single 
reading session for each patient by consensus of two 
gastrointestinal radiologists with 13 years and 5 years of 
experience in reading pelvic MR images. MRI readers 
were blinded to the clinicopathologic outcome and PET/
CT findings.
Regions of interest (ROIs) to cover the entire tumor 
volume were manually drawn slice by slice on pre-contrast 
T1-weighted images using the T2-weighted images as a 
guide [22]. Attention was placed to cover the entire lesion 
with the exclusion of peripheral fat, artefacts and blood 
vessels. Median values were recorded for all acquired 
tumor slices for each study.
For SIS analysis, for each TIC, the maximum 
signal difference (MSD) and wash out slope (WOS) were 
calculated, considering median value percentage change 
(ΔMSD=(MSD1 − MSD2)/MSD1×100 and ΔWOS= (WOS1 
− WOS2)/WOS1×100), their linear combination (equation 
1) was evaluated as described in our previously paper [13]:
D D DSIS  0.7780* MSD  0.6157* WOS = +  (1)
Semi-quantitative analyses were carried out using 
Matlab R2007a software (The Math-Works Inc., Natick, 
MA).
Evaluation of pathologic response
Details of how pathologic response assessment 
was performed have been described [8]. Briefly, surgical 
specimens containing the tumour were evaluated and 
scored according to tumour regression grade (TRG), 
as proposed by Mandard et al. [24] by two experienced 
pathologists who were not aware of MRI and FDG PET 
findings. Patients with a TRG 1 or 2 score were considered 
responders, whereas the remaining patients (TRG 3, 4, or 
5) were classified as non responders.
Statistical analysis
All quantitative data values were expressed as 
median ± standard deviation (SD) and compared with 
Mann-Whitney test. Chi-square test was performed to 
evaluate differences between pathologic responders (TRG 
1-2) and non-responders (TRG 3-4) regarding baseline 
patient and tumour characteristics. Receiver operating 
characteristic (ROC) curves were calculated using ΔSIS 
and ΔSUVmax and optimal thresholds were obtained 
maximizing the Youden index. Sensitivity, specificity, 
positive and negative predictive value (PPV and NPV), 
Oncotarget8152www.impactjournals.com/oncotarget
for ΔSIS and ΔSUV, to differentiate responders by non 
responders patient and pathological complete response 
(TRG1) by incomplete response (TRG2-4) were 
performed. Matched sample tables and the McNemar 
Chi-square tests were used to compare the performance. 
Spearman's rank correlation coefficient was used to 
evaluate correlation between ΔSIS and ΔSUVmax with TRG 
and pathological T stage (pT).
P value <0.05 was considered significant for all 
tests. All analyses were performed using Statistics 
Toolbox of Matlab R2007a (The Math-Works Inc., 
Natick, MA).
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